|
Active Research Studies
Currently Enrolling Patients
PFO ACCESS Registry
Sponsored By: AGA Medical
Patients with a condition called patent foramen ovale (PFO) in the heart who are treated with a closure device called the AMPLASTER PFO Occluder will be enrolled in this registry to assess the outcome of the procedure.
Primary Investigator: Robert Duerr, MD, FACC
Contact: Lea Bowman, CRC 208-685-2128
TRA 2 P-TIMI 50
Sponsored By: Schering-Plough
This study evaluates the safety and effectiveness of a new drug to prevent new serious cardiovascular events such as heart attack, stroke, and death in patients who already have a history of atherosclerosis involving the arteries of the heart, brain, or legs. This drug reduces clot formation by platelets.
Primary Investigator: David Hinchman, MD, FACC
Contact: Lea Bowman, CRC 208-685-2128
PROVIDE
Sponsored By: St. Jude Medical
Patients with heart disease who are at high risk for serious heart rhythm abnormalities and receive a St Jude Medical implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy device (CRT-D) may be eligible for enrollment in this study. The study will compare arrhythmia detection and treatment settings in these devices with the objective of minimizing unnecessary treatment shocks.
Primary Investigator: Karl Undesser, MD, PhD, FACC
Contact: Peggy Vieira, CRC 208-493-0321
APPRAISE
Sponsored by: Bristol-Myers Squibb
The purpose of this study is to determine if apixaban, a new anticoagulant drug, will reduce adverse cardiovascular events such as heart attack, stroke, and death in patients who have been hospitalized with chest pain or electrocardiogram changes due to reduced blood flow to the heart muscle.
Primary Investigator: Colin D. Lee, MD, MPH, FACC
Contact: Lea Bowman, CRC 208-685-2128
http://clinicaltrials.gov/ct2/show/study/NCT00831441?term=appraise&rank=1#locn
ENGAGE AF - TIMI 48
Sponsored By: Daiichi Sankyo
The purpose of this study is to compare the protection afforded by DU-176b, a new investigational anticoagulant drug, with warfarin in patients at risk for stroke or clots in their vascular system due to a heart rhythm abnormality called atrial fibrillation.
Primary Investigator: Colin Lee, MD, FACC
Contact: Tracy Arthur, RN CRC 208-685-2125
dal-OUTCOMES
JOSTENT Registry
Sponsored By: Abbott
Patients receiving JOSTENT Coronary Stent Graft or GraftMaster for treatment of perforations in coronary arteries or saphenous vein bypass grafts will be enrolled in this registry.
Primary Investigator: Colin Lee, MD, MPH, FACC
Contact: Tracy Arthur, RN, CRC 208-685-2125
Active Research Studies
Patient Enrollment Closed
AVANT GARDE
Sponsored By: Novartis
The purpose of this study is to compare the effects of two drugs, valsartan and aliskiren, to improve heart function. Patients who have persistent elevation of a biomarker substance in the blood called brain natriuretic peptide following an acute coronary event requiring hospitalization are eligible.
Primary Investigator: Charles Eiriksson, MD, FACC
Contact: Lea Bowman, CRC 208-685-2128
FREEDOM
Sponsored By: St. Jude Medical
This study evaluates the QuickOpt feature in patients treated with a St. Jude Medical cardiac resynchonization therapy device (CRT-D) to determine if clinical response is improved over standard of care.
Primary Investigator: Karl Undesser, MD, PhD, FACC
Contact: Vicki Graves, RN, CRC 208-685-2214
IMPROVE-HF Quality Improvement Initiative
Sponsored By: Medtronic
This is the largest heart failure quality improvement effort ever undertaken in the outpatient setting. Following the 2005 ACC/AHA Guideline Update for the Diagnosis and Management of Chronic Heart Failure, charts are reviewed in order to accomplish the following:
- track the utilization of heart failure medications, devices, and patient education,
- discover treatment gaps, and
- improve the understanding of how to identify patients for the indicated therapies.
Primary Investigator: Murali Bathina, MD, FACC
Contact: Vicki Graves, RN, CRC 208-685-2214
PREDICT
Sponsored By: CardioDx
The purpose of this study is to identify genetic markers in blood cells that predict the presence or absence of coronary artery disease. Patients undergoing their first coronary angiogram are eligible.
Primary Investigator: David Hinchman, MD, FACC
Contact: Lea Bowman, CRC 208-685-2128
TRITON TIMI-38 Coronary Stent Registry
Sponsored By: TIMI Study Group (Harvard University)
This registry will evaluate of the impact of different types of coronary stents used and the duration of treatment with platelet blocking medications on long-term health in patients who participated in the TRITON TIMI-38 Clinical Study.
Primary Investigator: David Hinchman, MD, FACC
Contact: Vicki Graves, RN, CRC 208-685-2214
[ to top]
|
